Login / Signup

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program.

Hai-Yan TuYi-Long Wu
Published in: OncoTargets and therapy (2020)
Tolerability-guided afatinib dose adjustment is an effective strategy to reduce TRAEs without affecting efficacy in Chinese patients.
Keyphrases
  • epidermal growth factor receptor
  • clinical trial
  • open label
  • advanced non small cell lung cancer
  • small cell lung cancer
  • tyrosine kinase
  • double blind
  • quality improvement
  • phase ii
  • study protocol